SIGNET-RING CELL CARCINOMA

This adverse event was reported 100 times

These drugs are most commonly taken by patients reporting SIGNET-RING CELL CARCINOMA:

# Drug Count
0 ADALIMUMAB 16
1 INFLIXIMAB 16
2 ADALIMUMAB-AATY 10
3 ADALIMUMAB-ADAZ 10
4 ADALIMUMAB-FKJP 10
5 USTEKINUMAB 9
6 PANTOPRAZOLE SODIUM 7
7 AZATHIOPRINE 6
8 CALCIUM CARBONATE 6
9 LISINOPRIL 6
See all common drugs associated with SIGNET-RING CELL CARCINOMA

SIGNET-RING CELL CARCINOMA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 OMEPRAOLE, SODIUM BICARBONATE 1 0.0032
1 NEOSTIGMINE METHYLSULFATE 1 0.0023
2 OMEPRAZOLE, SODIUM BICARBONATE 1 0.0011
3 FAMOTITINE 3 0.0010
4 BETAINE 1 0.0010
5 SODIUM FLUORIDE AND POTASSIUM NITRATE 1 0.0010
6 CAPLACIZUMAB 1 0.0006
7 VINBLASTINE SULFATE 1 0.0005
8 VELAGLUCERASE ALFA 1 0.0005
9 CLOMIPRAMINE HYDROCHLORIDE 2 0.0004
See all drugs enriched for association with SIGNET-RING CELL CARCINOMA

SIGNET-RING CELL CARCINOMA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Methylating Agent [EPC] 1 0.0010
1 mu-Opioid Receptor Agonist [EPC] 1 0.0003
2 Carnitine Analog [EPC] 1 0.0003
3 alpha-1 Adrenergic Agonist [EPC] 1 0.0002
4 Glinide [EPC] 2 0.0002
5 Cannabinoid [EPC] 2 0.0002
6 Anticholinergic [EPC] 3 0.0002
7 Allylamine Antifungal [EPC] 1 0.0001
8 Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC] 1 0.0001
9 Phenothiazine [EPC] 3 0.0001
See all drug classes enriched for association with SIGNET-RING CELL CARCINOMA